You searched for "Leukemia" from the Body Image.

Stage	Phase	Principal Investigator	Study prefix	Study number	Title (click hyperlink for more information)
	I	Meir Wetzler, MD	NCG	149209	(CALGB 20202) Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
	II	Meir Wetzler, MD	PH	120407	A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse or Previously Treated Myelodysplatic Syndrome
	III	Meir Wetzler, MD	NCG	129208	(S0521) A Randomized Trial of Maintenance Versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III
	III	Meir Wetzler, MD	NCG	132708	A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) And Consolidation (High-Dose Cytarbine) Chemotherapy + Midostaurin (PKC412) (IND # 101261) Or Placebo In Newly Diagnosed Patients < 60 years Of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)
	II	Meir Wetzler, MD	PH	109607	(2040AML201) A Phase II Simon Two-Stage Multicenter Study and Pilot Pharmacodynamic Investigation of GTI-2040 in Combination with High Dose Cytarabine (HiDAC) in Refractory and Relapse Acute Myeloid Leukemia (AML)
	III	Meir Wetzler, MD	PH	78406	(CLO34100405) A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and older with Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving Up to Two Prior Induction Regimens
	III	Martin Brecher, MD	NCG	92806	(COG AAML0531) A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents and Young Adults
	III	Martin Brecher, MD	NCG	56005	(COG AALL0331) Standard Risk B-precursor Acute Lymphoblastic Leukemia
	II	Meir Wetzler, MD	NCG / CALGB	97406	(CALGB 10503) Phase II of Maintenance Therapy with Decitabine (NSC #127716, IND #50733) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML < 60 years
N/A	III	Meir Wetzler, MD	NCG	41004	(ECOG E2902) A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over 60 in First Remission.
N/A	II	Meir Wetzler, MD	CALGB	C10001	A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, ST1571) (NSC #716051, IND 61135), and Transplantation for Adults with Newly Diagnosed PH Acute Lymphoblastic Leukemia by the CALGB and SWOG
	II	Meir Wetzler, MD	PH	107907	INNO-507-P2 A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy with ATRA and Arsenic Trioxide
	III	Martin Brecher, MD	NCG	123307	(COG AALL0433) Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
	II	Meir Wetzler, MD	NCG / CALGB	124607	(CALGB 10403) An Intergroup Phase II Clinical Trial For Adolescents And Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)
	II	Eunice Wang, MD	NCG	143208	(CALGB 10502) Dose Escalation and Phase II Study of Bortezomib (IND # 58443, NCI # 681239) Added to Standard Danorubicin and Cytarbine Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years
	III	Meir Wetzler, MD	PH	120107	Phase 3 Open-Label Randomized Study of Amonafide L-Malate in Combination with Cytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML)
	II	Meir Wetzler, MD	NCG	144808	A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (S0535)
	I/II	Meir Wetzler, MD	I	153609	A Phase 1/2, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects with Refractory Hematologic Malignancies
	II	Meir Wetzler, MD	I	132208	A Phase II Study Evaluating Mechanisms of Resistance Following Treatment with Clofarabine and Daunorubicin in Newly Diagnosed Adult Acute Myeliod Leukemia Patients>or =to 60 Year Old

Total number of Clinical Trials found: 19

Return to Search page